{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:41:09Z","timestamp":1775479269179,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Treatment decisions in patients with small cell lung cancer (SCLC) are made based on the extent of the disease. However, the outcome varies among patients at the same stage. A simple tool to predict outcomes in SCLC patients would be helpful for clinical decision-making. In recent years, several prognostic scores have been proposed. In this study, we evaluated the different prognostic factors in an unselected real-world cohort of patients. We retrospectively collected clinical, radiological and laboratory data from 92 patients diagnosed with SCLC. Univariate and multivariate cox regression analyses of survival were performed to assess the prognostic value of relevant clinical and laboratory factors for SCLC. Furthermore, we examined the association between eight published prognostic scores for SCLC and overall survival (OS). In the overall cohort, the median OS was 10.3 months (20.9 months and 9.2 months for limited disease (LD) SCLC and extensive disease (ED) SCLC, respectively). In univariate analysis, initial staging, number of metastatic sites and presence of liver, bone and adrenal gland metastases were significantly associated with worse OS. Of the established laboratory markers, albumin, alkaline phosphatase and hyponatremia but not lactate dehydrogenase (LDH) significantly predicted OS. All published prognostic scores, with the exception of the Glasgow Prognostic Score, did not significantly predict OS. In multivariate analysis, age, staging and alkaline phosphatase serum levels showed significant association with OS. We could not confirm the prognostic significance of most of the published complex prognostic scores. We therefore recommend using simple clinical and laboratory factors instead of complex scores to estimate the prognosis of SCLC patients in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers14112625","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:50:22Z","timestamp":1653555022000},"page":"2625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set"],"prefix":"10.3390","volume":"14","author":[{"given":"Raphael","family":"Hagmann","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Lung Cancer Center Basel, Comprehensive Cancer Center, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-9340","authenticated-orcid":false,"given":"Sacha I.","family":"Rothschild","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University Hospital Basel, 4031 Basel, Switzerland"},{"name":"Lung Cancer Center Basel, Comprehensive Cancer Center, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung Cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2003.12.006","article-title":"Small cell lung cancer: State of the art and future perspectives","volume":"45","author":"Stupp","year":"2004","journal-title":"Lung Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3.0.CO;2-P","article-title":"The international system for staging lung cancer","volume":"18","author":"Mountain","year":"2000","journal-title":"Semin. Surg. Oncol."},{"key":"ref_4","first-page":"647","article-title":"Small-cell lung cancer: Treatment progress and prospects","volume":"12","author":"Clark","year":"1998","journal-title":"Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11912-010-0120-5","article-title":"Small Cell Lung Cancer: Past, Present, and Future","volume":"12","author":"Rodriguez","year":"2010","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1517\/14656566.2014.957180","article-title":"Advances in pharmacotherapy of small cell lung cancer","volume":"15","author":"Kalemkerian","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Popat","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Oze, I., Hotta, K., Kiura, K., Ochi, N., Takigawa, N., Fujiwara, Y., Tabata, M., and Tanimoto, M. (2009). Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007835"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Dvorkin","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1758834013517413","article-title":"Relapsed small cell lung cancer: Treatment options and latest developments","volume":"6","author":"Asai","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.7150\/jca.13080","article-title":"Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide Additionally, Vincristine (ACO)\u2014A Single Center Experience","volume":"6","author":"Hagmann","year":"2015","journal-title":"J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1515\/raon-2015-0027","article-title":"The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer","volume":"50","author":"Sodja","year":"2016","journal-title":"Radiol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10637-017-0446-z","article-title":"Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: Exploratory analysis of a phase II study","volume":"35","author":"Salgia","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fonc.2013.00158","article-title":"Epigenetic Therapy in Lung Cancer\u2014Role of microRNAs","volume":"3","author":"Rothschild","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1008212826956","article-title":"Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients","volume":"8","author":"Maestu","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.2910390204","article-title":"Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients","volume":"39","author":"Cerny","year":"1987","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.7150\/jca.29319","article-title":"Comparison of the Prognostic Value of Systemic Inflammation Response Markers in Small Cell Lung Cancer Patients","volume":"10","author":"Zhou","year":"2019","journal-title":"J. Cancer"},{"key":"ref_19","first-page":"1","article-title":"Inflammation scores as prognostic biomarkers in small cell lung cancer: A systematic review and meta-analysis","volume":"10","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lu, Y., Jiang, J., and Ren, C. (2020). The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230979"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0169-5002(89)90156-6","article-title":"Staging and prognostic factors in small cell lung cancer: A consensus report","volume":"5","author":"Stahel","year":"1989","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.cllc.2015.03.005","article-title":"Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients with Small-Cell Lung Cancer","volume":"16","author":"He","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3892\/mco.2017.1261","article-title":"Modified glasgow prognostic score in patients with small-cell lung cancer","volume":"7","author":"Kurishima","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0169-5002(86)80079-4","article-title":"Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung","volume":"2","author":"Souhami","year":"1986","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.2014.317","article-title":"The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer","volume":"111","author":"Kang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s13277-014-2973-y","article-title":"The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients","volume":"36","author":"Hong","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12032-009-9174-3","article-title":"Survival and prognostic factors in small cell lung cancer","volume":"27","author":"Li","year":"2009","journal-title":"Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.1989.7.3.344","article-title":"Prognostic factors in small-cell carcinoma of the lung: An analysis of 1521 patients","volume":"7","author":"Spiegelman","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2005.03.171","article-title":"Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer","volume":"23","author":"Singh","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/curroncol28010036","article-title":"Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes","volume":"28","author":"Moser","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10408363.2011.599831","article-title":"Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer","volume":"48","author":"Allin","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.2012.292","article-title":"A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer","volume":"107","author":"Proctor","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.2147\/CMAR.S180990","article-title":"Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy","volume":"10","author":"Bernhardt","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12013-014-9845-3","article-title":"Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung Cancer","volume":"69","author":"Wang","year":"2014","journal-title":"Cell Biophys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/JTO.0000000000000585","article-title":"Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers","volume":"10","author":"Xie","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/LCTT.S142880","article-title":"Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer","volume":"8","author":"Minami","year":"2017","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000502681","article-title":"Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute","volume":"64","author":"Sonehara","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s13277-014-2623-4","article-title":"A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer","volume":"36","author":"Zhou","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2012.04.008","article-title":"The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer","volume":"77","author":"Gioulbasanis","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/0284186X.2019.1711165","article-title":"Treatment patterns and survival outcomes for small-cell lung cancer patients\u2014A Swedish single center cohort study","volume":"59","author":"Tendler","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00262-020-02565-0","article-title":"Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort","volume":"69","author":"Schmid","year":"2020","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:49Z","timestamp":1760138329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112625"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112625","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}